Treanda Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Alerts
• Clinical Trials
• Forums

Zanubrutinib Followed Zanubrutinib Plus FCR (Fludarabine Cyclophosphamide and Rituximab) / Zanubrutinib Plus BR(Bendamustine and Rituximab) in Newly Diagnosed Symptomatic CLL/SLL
Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Newly Diagnosed Interventions:   Drug: Zanubrutinib, Fludarabine, cyclophosphamide and rituximab;   Drug: Zanubrutinib, bendamustine, rituximab Sponsor:   Institute of Hematology & Blood Diseases Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2022 Category: Research Source Type: clinical trials